drugset / Trial / NCT00379288

Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)

NCT00379288

Phase 3 Completed 404 enrolled Organon and Co
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) metered dose inhaler (MDI) 200/10 mcg twice-a-day (BID) and MF/F MDI 400/10 mcg BID and two doses of fluticasone/salmeterol combination (F/SC) (250/50 mcg BID and 500/50 mcg BID) in subjects with persistent asthma who require maintenance treatment on inhaled glucocorticosteroids (ICS); evaluator-blind. In addition, the extrapulmonary effects on 24-hour plasma cortisol area under curve (AUC), of MF/F MDI 200/10 mcg BID, MF/F MDI 400/10 mcg BID, F/SC MDI 250/50 mcg BID, and F/SC MDI 500/50 mcg BID will be evaluated.

Timeline

Start
2006-06
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone propionate Other / unclassified 250 ug
Comparator Fluticasone propionate Other / unclassified 500 ug
Subject Formoterol Other / unclassified 10 ug Inhaled
Subject Mometasone furoate Other / unclassified 200 ug Inhaled
Subject Mometasone furoate Other / unclassified 400 ug Inhaled
Comparator Salmeterol Other / unclassified 50 ug

Indications